Nektar Therapeutics (NASDAQ:NKTR) CAO Jillian B. Thomsen sold 1,928 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $31.37, for a total transaction of $60,481.36. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Jillian B. Thomsen also recently made the following trade(s):
- On Tuesday, February 19th, Jillian B. Thomsen sold 1,808 shares of Nektar Therapeutics stock. The stock was sold at an average price of $42.39, for a total transaction of $76,641.12.
Shares of Nektar Therapeutics stock traded up $0.68 during trading hours on Friday, reaching $32.02. The company’s stock had a trading volume of 1,480,671 shares, compared to its average volume of 1,752,666. Nektar Therapeutics has a one year low of $29.22 and a one year high of $92.17. The firm has a market capitalization of $5.91 billion, a price-to-earnings ratio of 8.47 and a beta of 2.96. The company has a current ratio of 14.94, a quick ratio of 14.83 and a debt-to-equity ratio of 0.21.
Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.03. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. The firm had revenue of $28.22 million for the quarter, compared to analyst estimates of $25.45 million. During the same period last year, the firm earned ($0.60) earnings per share. On average, research analysts forecast that Nektar Therapeutics will post -3.14 EPS for the current year.
Several institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. lifted its position in shares of Nektar Therapeutics by 150.2% during the first quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 479 shares in the last quarter. Quantamental Technologies LLC bought a new position in shares of Nektar Therapeutics during the first quarter valued at about $27,000. CSat Investment Advisory L.P. lifted its position in shares of Nektar Therapeutics by 279.2% during the fourth quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 790 shares in the last quarter. Laurel Wealth Advisors LLC bought a new position in shares of Nektar Therapeutics during the fourth quarter valued at about $39,000. Finally, Sandy Spring Bank bought a new position in shares of Nektar Therapeutics during the fourth quarter valued at about $59,000. 94.90% of the stock is currently owned by hedge funds and other institutional investors.
NKTR has been the topic of several research analyst reports. BidaskClub raised shares of Nektar Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, April 5th. BMO Capital Markets initiated coverage on shares of Nektar Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $75.00 target price on the stock. Mizuho reissued a “buy” rating and set a $81.00 target price on shares of Nektar Therapeutics in a research note on Friday, March 1st. HC Wainwright reissued a “hold” rating and set a $47.00 target price on shares of Nektar Therapeutics in a research note on Tuesday, February 19th. Finally, TheStreet raised shares of Nektar Therapeutics from a “d+” rating to a “c” rating in a research note on Thursday, February 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $69.73.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Story: What is a Stop Order?
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.